Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel G Bichet

Showing results (131-140 of 144) with videos related to

Pageof 15
Sort By:
Medecine Sciences : M/S|June 4, 2015
[The 2000 years]Marc Peschanski, Michel Bergeron, André Boué, et al.
Kidney International|June 14, 2013
Evidence of a third ADPKD locus is not supported by re-analysis of designated PKD3 familiesBinu M Paul, Mark B Consugar, Moonnoh Ryan Lee, et al.
Molecular Genetics and Metabolism|December 3, 2009
A validated disease severity scoring system for Fabry diseaseEdward H Giannini, Atul B Mehta, Max J Hilz, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|August 19, 2010
How well does urinary lyso-Gb3 function as a biomarker in Fabry disease?Christiane Auray-Blais, Aimé Ntwari, Joe T R Clarke, et al.
Journal of Medical Genetics|February 14, 2018
Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort studyMaarten Arends, Marieke Biegstraaten, Christoph Wanner, et al.
Journal of Medical Genetics|March 20, 2016
Time to treatment benefit for adult patients with Fabry disease receiving agalsidase β: data from the Fabry RegistryAlberto Ortiz, Ademola Abiose, Daniel G Bichet, et al.
Plos One|May 9, 2015
Characterization of early disease status in treatment-naive male paediatric patients with Fabry disease enrolled in a randomized clinical trialFrits A Wijburg, Bernard Bénichou, Daniel G Bichet, et al.
Plos One|August 8, 2015
Oral Migalastat HCl Leads to Greater Systemic Exposure and Tissue Levels of Active α-Galactosidase A in Fabry Patients when Co-Administered with Infused AgalsidaseDavid G Warnock, Daniel G Bichet, Myrl Holida, et al.
Molecular Genetics and Metabolism|April 17, 2019
Low-dose agalsidase beta treatment in male pediatric patients with Fabry disease: A 5-year randomized controlled trialUma Ramaswami, Daniel G Bichet, Lorne A Clarke, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|September 23, 2016
The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastatElfrida R Benjamin, Maria Cecilia Della Valle, Xiaoyang Wu, et al.
Pageof 15

Showing results (131-140 of 144) with videos related to

Sort By:
Pageof 15
Medecine Sciences : M/S|June 4, 2015
[The 2000 years]Marc Peschanski, Michel Bergeron, André Boué, et al.
Kidney International|June 14, 2013
Evidence of a third ADPKD locus is not supported by re-analysis of designated PKD3 familiesBinu M Paul, Mark B Consugar, Moonnoh Ryan Lee, et al.
Molecular Genetics and Metabolism|December 3, 2009
A validated disease severity scoring system for Fabry diseaseEdward H Giannini, Atul B Mehta, Max J Hilz, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|August 19, 2010
How well does urinary lyso-Gb3 function as a biomarker in Fabry disease?Christiane Auray-Blais, Aimé Ntwari, Joe T R Clarke, et al.
Journal of Medical Genetics|February 14, 2018
Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort studyMaarten Arends, Marieke Biegstraaten, Christoph Wanner, et al.
Journal of Medical Genetics|March 20, 2016
Time to treatment benefit for adult patients with Fabry disease receiving agalsidase β: data from the Fabry RegistryAlberto Ortiz, Ademola Abiose, Daniel G Bichet, et al.
Plos One|May 9, 2015
Characterization of early disease status in treatment-naive male paediatric patients with Fabry disease enrolled in a randomized clinical trialFrits A Wijburg, Bernard Bénichou, Daniel G Bichet, et al.
Plos One|August 8, 2015
Oral Migalastat HCl Leads to Greater Systemic Exposure and Tissue Levels of Active α-Galactosidase A in Fabry Patients when Co-Administered with Infused AgalsidaseDavid G Warnock, Daniel G Bichet, Myrl Holida, et al.
Molecular Genetics and Metabolism|April 17, 2019
Low-dose agalsidase beta treatment in male pediatric patients with Fabry disease: A 5-year randomized controlled trialUma Ramaswami, Daniel G Bichet, Lorne A Clarke, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|September 23, 2016
The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastatElfrida R Benjamin, Maria Cecilia Della Valle, Xiaoyang Wu, et al.
Pageof 15